OraSure Technologies (OSUR) Expected to Announce Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) is projected to issue its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $26.4430 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

OraSure Technologies Stock Performance

Shares of OSUR stock opened at $2.75 on Wednesday. The firm has a market capitalization of $197.26 million, a price-to-earnings ratio of -3.44 and a beta of 0.87. OraSure Technologies has a one year low of $2.08 and a one year high of $4.22. The company has a 50 day moving average price of $2.62 and a 200 day moving average price of $2.79.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Stephens dropped their price objective on OraSure Technologies from $3.50 to $3.00 and set an “equal weight” rating for the company in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d)” rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, OraSure Technologies has a consensus rating of “Reduce” and an average price target of $3.00.

Institutional Investors Weigh In On OraSure Technologies

A number of large investors have recently added to or reduced their stakes in OSUR. Prudential Financial Inc. acquired a new position in OraSure Technologies in the 2nd quarter worth $31,000. Amundi purchased a new stake in shares of OraSure Technologies during the first quarter worth about $47,000. HighTower Advisors LLC acquired a new position in shares of OraSure Technologies in the fourth quarter worth about $49,000. BNP Paribas Financial Markets boosted its holdings in OraSure Technologies by 102.2% in the third quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 7,720 shares during the last quarter. Finally, Private Advisor Group LLC purchased a new stake in OraSure Technologies during the 3rd quarter worth approximately $57,000. 93.50% of the stock is owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.